VαMPiRE Project Makes Strides in Parkinson’s Detection

SYNLAB, a leader in medical diagnostics in Europe, announces the commencement of a clinical trial for the VαMPiRE project, aimed at early detection of Parkinson’s disease. Funded by €8 million from the EU, this initiative seeks to create a non-invasive diagnostic test by studying α-synuclein isoforms. The first patient enrolment marks a critical milestone, and the trial will involve 600 PD patients and 600 healthy participants.

SYNLAB's Genetics Department in Italy leads genomic analysis, utilizing advanced AI for accurate data algorithms. The project reflects significant EU trust in enhancing diagnostic capabilities. CEO Mathieu Floreani emphasizes the potential for improved patient outcomes, while Dr. Iris Faull highlights the consortium’s contribution to medical innovation. This collaboration promises advancements in global health through effective early detection methods.